Key result
DES and adjunctive pharmacology improve adverse event rates in diabetic patients with ACS.
Drug-eluting stents combined with adjunctive pharmacological strategies improve adverse event rates in patients with diabetes and acute coronary syndromes.
Supports adjunctive pharmacotherapy with DES in diabetic ACS; leaves open optimal regimens and long-term outcomes.
Diabetes mellitus has reached epidemic proportions worldwide. Patients with diabetes are at increased risk for acute coronary syndromes, and these syndromes lead to frequent morbidity and cardiovascular mortality. Emerging adjunctive pharmacological strategies coupled with the drug-eluting stent platform have resulted in improved adverse event rates for this high-risk group. This review will concentrate on the historical data associated with acute coronary syndromes in diabetes mellitus, focusing on revascularisation, drug-eluting stents and antiplatelet therapies.
No takes yet. Share an insight, caveat, or question.
Steven P. Marso (2005) conducted a review in Acute coronary syndromes in diabetes mellitus. Revascularisation, drug-eluting stents, and antiplatelet therapies was evaluated. Adjunctive pharmacological strategies and drug-eluting stents have improved adverse event rates for patients with diabetes and acute coronary syndromes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: